12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Simeprevir regulatory update

Johnson & Johnson's Janssen Research & Development LLC unit submitted an NDA to FDA for simeprevir to treat HCV genotype 1 infection....

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >